Latest news
Loading news…
Cirrus Therapeutics
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Cambridge, Massachusetts, United States Founded 2022 1-10 employees For Profit
Cirrus Therapeutics is a Biotechnology Research firm diganosing and treating eye diseases affecting ocular immune system.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Patents
0
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 4
- Patents granted
- 0
- Trademarks
- 0
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $98K
Company Info
- Founded
- 2022
- Employees
- 1-10
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 2
- News articles
- 8
- HQ
- Cambridge, Massachusetts, United States
- Region
- Greater Boston Area, East Coast, New England
Signals & Scores
- Heat score
- Low
- Growth score
- Low
- Trend (7d)
- -0.4
- Trend (30d)
- -1.5
- Trend (90d)
- -2.1
- Last leadership hire
- Mar 3, 2026
Key People at Cirrus Therapeutics
Director, Pipeline and Site Head, Singapore
Co-Founder and CEO
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Cirrus Therapeutics
Loading news…
FAQs about Cirrus Therapeutics
People who checked this page also checked these
Browse the full Acquirezy directory.